Research Groups

Khalaf, A., de Beauchamp, L., Kalkman, E., Rattigan, K., Himonas, E., Jones, J., James, D., Shokry, E. S. A., Scott, M. T., Dunn, K., Tardito, S., Copland, M., Sumpton, D., Shanks, E., Helgason, V. (2024) Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia. Science Translational Medicine, 16, (doi: 10.1126/scitranslmed.adi5336)

Anastasopoulou, S., Swann, G., Andres-Jensen, L., Attarbaschi, A., Barzilai-Birenboim, S., Erdelyi, D. J., Escherich, G., Hamadeh, L., Harila, A., Lopez-Lopez, E., McGowan, S., Möricke, A., Putti, C., Sagi, J. C., Schmiegelow, K., Ullrich, N. J., van der Sluis, I. M., ul-Ain Wahid, Q., Winick, N., Sramkova, L., Zalcberg, Y., Zapotocka, E., Bhojwani, D., Halsey, C. (2024) Severe steroid related neuropsychiatric symptoms during pediatric acute lymphoblastic leukemia therapy - an observational Ponte di Legno Toxicity Working Group Study. British Journal of Haematology,

Wiesheu, R. et al. (2024) IL-27 maintains cytotoxic Ly6C+ T cells that arise from immature precursors. EMBO Journal, (doi: 10.1038/s44318-024-00133-1)

Busch, C., Nyamondo, K., Wheadon, H. (2024) Complexities of modelling the bone marrow microenvironment to facilitate haematopoietic research. Experimental Hematology, (doi: 10.1016/j.exphem.2024.104233)

Patterson, S.D., Massett, M., Huang, X., Jørgensen, H.G., Michie, A.M. (2024) The MYC–NFATC2 axis maintains the cell cycle and mitochondrial function in acute myeloid leukaemia cells. Molecular Oncology, (doi: 10.1002/1878-0261.13630)

Zarou, M. M., Rattigan, K. M., Sarnello, D., Shokry, E., Dawson, A., Ianniciello, A., Dunn, K., Copland, M., Sumpton, D., Vazquez, A., Helgason, V. (2024) Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1-mediated purine sensing. Nature Communications, 15, (doi: 10.1038/s41467-024-46114-0)

Vringer, E., Heilig, R., Riley, J. S., Black, A., Cloix, C., Skalka, G., Montes-Gómez, A. E., Aguado, A., Lilla, S., Walczak, H., Gyrd-Hansen, M., Murphy, D. J., Huang, D. T., Zanivan, S., Tait, S. W.G. (2024) Mitochondrial outer membrane integrity regulates a ubiquitin-dependent and NF-κB-mediated inflammatory response. EMBO Journal, 43, pp. 904-930. (doi: 10.1038/s44318-024-00044-1)

Dawson, A. et al. (2024) Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche. Nature Communications, 15, (doi: 10.1038/s41467-024-45471-0)

Scott, M. T., Liu, W., Mitchell, R., Clarke, C. J., Kinstrie, R., Warren, F., Almasoudi, H., Stevens, T., Dunn, K., Pritchard, J., Drotar, M. E., Michie, A. M., Jorgensen, H. G., Higgins, B., Copland, M., Vetrie, D. (2024) Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease. Nature Communications, 15, (doi: 10.1038/s41467-024-44771-9)

Malik, N., Hay, J., Almuhanna, H. N.B., Dunn, K. M., Lees, J., Cassels, J., Li, J., Nakagawa, R., Sansom, O. J., Michie, A. M. (2023) mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia. Leukemia, 37, pp. 2414-2425. (doi: 10.1038/s41375-023-02043-3)

Busch, C., Mulholland, T., Zagnoni, M., Dalby, M., Berry, C., Wheadon, H. (2023) Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach. Cell Communication and Signaling, 21, (doi: 10.1186/s12964-023-01363-2)

Copland, M., Ariti, C., Thomas, I. F., Upton, L., Sydenham, M., Mehta, P., Islam, S., Kjeldsen, L., Burnett, A. K., Hills, R. K., Russell, N., Dennis, M. (2023) A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial. British Journal of Haematology, (doi: 10.1111/bjh.19220)

Zarou, M. M., Dawson, A., Prasad, B., Bittencourt-Silvestre, J., Zerbst, D., Rodriguez Blanco, G., Scott, M., Dunn, K., Krishnan, V., Copland, M., Vetrie, D., Bhatia, R., Coffelt, S., Ong, S. T., Wheadon, H., Zanivan, S., Kirschner, K., Helgason, G. V. (2023) Leukaemia Exposure Alters the Transcriptional Profile and Function of Macrophages in the Bone Marrow Niche. (doi: 10.1182/blood-2023-181630)

Rattigan, K. M., Zarou, M. M., Brabcova, Z., Prasad, B., Zerbst, D., Sarnello, D., Kalkman, E. R., Ianniciello, A., Scott, M. T., Dunn, K., Shokry, E., Sumpton, D., Copland, M., Tardito, S., Vande Voorde, J., Mussai, F., Cheng, P., Helgason, G. V. (2023) Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells. EMBO Reports, 24, (doi: 10.15252/embr.202256279)

Nikolatou, K., Sandilands, E., Román-Fernández, A., Cumming, E. M., Freckmann, E., Lilla, S., Buetow, L., McGarry, L., Neilson, M., Shaw, R., Strachan, D., Miller, C., Huang, D. T., Mcneish, I. A., Norman, J. C., Zanivan, S., Bryant, D. M. (2023) PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer. EMBO Journal, 42, (doi: 10.15252/embj.2023113987)

Rattigan, K. M., Brabcova, Z., Sarnello, D., Zarou, M. M., Roy, K., Kwan, R., de Beauchamp, L., Dawson, A., Ianniciello, A., Khalaf, A., Kalkman, E. R., Scott, M. T., Dunn, K., Sumpton, D., Michie, A. M., Copland, M., Tardito, S., Gottlieb, E., Helgason, G. V. (2023) Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells. Nature Communications, 14, (doi: 10.1038/s41467-023-40222-z)

Darici, S., Jørgensen, H. G., Huang, X., Serafin, V., Antolini, L., Barozzi, P., Luppi, M., Forghieri, F., Marmiroli, S., Zavatti, M. (2023) Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells. Advances in Biological Regulation, 89, (doi: 10.1016/j.jbior.2023.100974)

Yang, F., Nourse, C., Helgason, G. V., Kirschner, K. (2023) Unraveling heterogeneity in the aging hematopoietic stem cell compartment: an insight from single-cell approaches. HemaSphere, 7, (doi: 10.1097/hs9.0000000000000895)

Rattigan, K. M., Zarou, M.-M., Helgason, G. V. (2023) Metabolism in stem cell driven leukaemia: parallels between haematopoiesis and immunity. Blood, 141, pp. 2553-2565. (doi: 10.1182/blood.2022018258)

Lees, J., Hay, J., Moles, M. W., Michie, A. M. (2023) The discrete roles of individual FOXO transcription factor family members in B-cell malignancies. Frontiers in Immunology, 14, (doi: 10.3389/fimmu.2023.1179101)

Woodley, K., Dillingh, L. S., Giotopoulos, G., Madrigal, P., Rattigan, K. M., Philippe, C., Dembitz, V., Magee, A. M. S., Asby, R., van de Lagemaat, L. N., Mapperley, C., James, S. C., Prehn, J. H. M., Tzelepis, K., Rouault-Pierre, K., Vassiliou, G. S., Kranc, K. R., Helgason, G. V., Huntly, B. J. P., Gallipoli, P. (2023) Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death. Nature Communications, 14, (doi: 10.1038/s41467-023-37652-0)

Fernando, F., Innes, A. J., Claudiani, S., Pryce, A., Hayden, C., Byrne, J., Gallipoli, P., Copland, M., Apperley, J. F., Milojkovic, D. (2023) The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia. Bone Marrow Transplantation, 58, pp. 826-828. (doi: 10.1038/s41409-023-01975-9)

Patterson, S. D., Copland, M. (2023) The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities. Current Hematologic Malignancy Reports, 18, pp. 19-32. (doi: 10.1007/s11899-023-00688-6)

Mussai, F., De Santo, C., Cheng, P., Thomas, I. F., Ariti, C., Upton, L., Scarpa, U., Stavrou, V., Sydenham, M., Burnett, A. K., Knapper, S. K., Mehta, P., McMullin, M. F., Copland, M., Russell, N. H., Dennis, M. (2023) A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: results from the LI-1 trial. British Journal of Haematology, 200, pp. 573-578. (doi: 10.1111/bjh.18560)

Villar, V. H., Allega, M. F., Deshmukh, R., Ackermann, T., Nakasone, M. A., Vande Voorde, J., Drake, T. M., Oetjen, J., Bloom, A., Nixon, C., Müller, M., May, S., Tan, E. H., Vereecke, L., Jans, M., Blancke, G., Murphy, D. J., Huang, D. T., Lewis, D. Y., Bird, T. G., Sansom, O. J., Blyth, K., Sumpton, D., Tardito, S. (2023) Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology, 19, pp. 292-300. (doi: 10.1038/s41589-022-01154-9)

Stavrou, V., Fultang, L., Booth, S., De Simone, D., Bartnik, A., Scarpa, U., Gneo, L., Panetti, S., Potluri, S., Almowaled, M., Barlow, J., Jankevics, A., Lloyd, G., Southam, A., Priestman, D. A., Cheng, P., Dunn, W., Platt, F., Endou, H., Craddock, C., Keeshan, K., Mussai, F., De Santo, C. (2023) Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment. Cancer Immunology, Immunotherapy, 72, pp. 543-560. (doi: 10.1007/s00262-022-03268-4)

Leak, S., Horne, G., Copland, M. (2023) Targeting BCR-ABL1-positive leukaemias, a review article. Cambridge Prisms: Precision Medicine, 1, (doi: 10.1017/pcm.2023.9)

Schmidt, T., Dąbrowska, A., Waldron, J. A., Hodge, K., Koulouras, G., Gabrielsen, M., Munro, J., Tack, D. C., Harris, G., McGhee, E., Scott, D., Carlin, L. M., Huang, D., Le Quesne, J., Zanivan, S., Wilczynska, A., Bushell, M. (2023) eIF4A1-dependent mRNAs employ purine-rich 5’UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation. Nucleic Acids Research, 51, pp. 1859-1879. (doi: 10.1093/nar/gkad030)

Chen, H. et al. (2023) PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371. Blood Vessels, 141, pp. 244-259. (doi: 10.1182/blood.2022016580)

Mehta, P., Telford, N., Wragg, C., Dillon, R., Freeman, S., Finnegan, D., Hamblin, A., Copland, M., Knapper, S. (2023) A British Society for Haematology good practice paper: Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. British Journal of Haematology, 200, pp. 150-159. (doi: 10.1111/bjh.18516)

Kowalczyk, D., Nakasone, M. A., Smith, B. O., Huang, D. T. (2022) Bivalent binding of p14ARF to MDM2 RING and acidic domains inhibits E3 ligase function. Life Science Alliance, 5, (doi: 10.26508/lsa.202201472)

Cousins, A., Olivares, O., Markert, E., Manoharan, A., Bubnova, X., Bresolin, S., Degn, M., Li, Z., Silvestri, D., McGregor, G., Tumanov, S., Sumpton, D., Kamphorst, J. J., Michie, A. M., Herzyk, P., Valsecchi, M. G., Yeoh, A. E., Schmiegelow, K., te Kronnie, G., Gottlieb, E., Halsey, C. (2022) Central nervous system involvement in childhood acute lymphoblastic leukemia is linked to upregulation of cholesterol biosynthetic pathways. Leukemia, 36, pp. 2903-2907. (doi: 10.1038/s41375-022-01722-x)

Thastrup, M., Duguid, A., Mirian, C., Schmiegelow, K., Halsey, C. (2022) Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions. Leukemia, 36, pp. 2751-2768. (doi: 10.1038/s41375-022-01714-x)

Hay, J., Tarafdar, A., Holroyd, A. K., Moka, H. A., Dunn, K. M., Alshayeb, A., Lloyd, B. H., Cassels, J., Malik, N., Khan, A. F., Sou, I., Lees, J., Almuhanna, H. N.B., Kalakonda, N., Slupsky, J. R., Michie, A. M. (2022) PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signalling. Cancers, 14, (doi: 10.3390/cancers14236006)

Copland, M. (2022) Treatment of blast phase chronic myeloid leukaemia: a rare and challenging entity. British Journal of Haematology, 199, pp. 665-678. (doi: 10.1111/bjh.18370)

Parry, N., Busch, C., Aßmann, V., Cassels, J., Hair, A., Helgason, G. V., Wheadon, H., Copland, M. (2022) BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. Cell Death Discovery, 8, (doi: 10.1038/s41420-022-01211-1)

Jamieson, S. A., Pudjihartono, M., Horne, C. R., Viloria, J. S., Dunlop, J. L., McMillan, H. D., Day, R. C., Keeshan, K., Murphy, J. M., Mace, P. D. (2022) Nanobodies identity an activated state of the TRIB2 pseudokinase. Structure, 30, pp. 1518-1529.e5. (doi: 10.1016/j.str.2022.08.006)

Gómez-Castañeda, E., Hopcroft, L. E.M., Rogers, S., Munje, C., Bittencourt-Silvestre, J., Copland, M., Vetrie, D., Holyoake, T., Jørgensen, H. G. (2022) Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapy. Cancers, 14, (doi: 10.3390/cancers14215253)

Dennis, M., Copland, M., Kaur, H., Kell, J., Nikolousis, E., Mehta, P., Palanicawandar, R., Potter, V., Raj, K., Thomas, I., Wilson, A. (2022) Management of older patients with frailty and acute myeloid leukaemia: a British Society for Haematology good practice paper. British Journal of Haematology, 199, pp. 205-221. (doi: 10.1111/bjh.18369)

Lebecque, B., Bourgne, C., Munje, C., Berger, J., Tassin, T., Cony-Makhoul, P., Guerci, A., Johnson-Ansah, H., Liu, W., Saugues, S., Tchirkov, A., Vetrie, D., Copland, M., Berger, M. G. (2022) The spliceosome: a new therapeutic target in chronic myeloid leukaemia. Cancers, 14, (doi: 10.3390/cancers14194695)

Pal, D., Blair, H., Parker, J., Hockney, S., Beckett, M., Singh, M., Tirtakusuma, R., Nelson, R., McNeill, H., Angel, S. H., Wilson, A., Nizami, S., Nakjang, S., Zhou, P., Schwab, C., Sinclair, P., Russell, L. J., Coxhead, J., Halsey, C., Allan, J. M., Harrison, C. J., Moorman, A. V., Heidenreich, O., Vormoor, J. (2022) hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Cell Reports Medicine, 3, (doi: 10.1016/j.xcrm.2022.100717)

Nyamondo, K., Wheadon, H. (2022) Microenvironment alterations through time leading to myeloid malignancies. British Journal of Pharmacology, (doi: 10.1111/bph.15924)

Robertson, N. A., Latorre-Crespo, E., Terradas-Terradas, M., Lemos-Portela, J., Purcell, A. C., Livesey, B. J., Hillary, R. F., Murphy, L., Fawkes, A., MacGillivray, L., Copland, M., Marioni, R. E., Marsh, J. A., Harris, S. E., Cox, S. R., Deary, I. J., Schumacher, L. J., Kirschner, K., Chandra, T. (2022) Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects. Nature Medicine, 28, pp. 1439-1446. (doi: 10.1038/s41591-022-01883-3)

Ianniciello, A., Helgason, G. V. (2022) Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia. Autophagy, 18, pp. 1734-1736. (doi: 10.1080/15548627.2022.2041152)

Pirillo, C., Birch, F., Tissot, F., Anton, S. G., Haltalli, M., Tini, V., Kong, I., Piot, C., Partridge, B., Pospori, C., Keeshan, K., Santamaria, S., Hawkins, E., Falini, B., Marra, A., Duarte, D., Lee, C. F., Roberts, E., Celso, C. L. (2022) Metalloproteinase inhibition reduces AML growth, prevents stem cell loss and improves chemotherapy effectiveness. Blood Advances, 6, pp. 3126-3141. (doi: 10.1182/bloodadvances.2021004321)

Lal, R., Ritchie, J., Richmond, L., Keeshan, K. (2022) Detecting endogenous TRIB2 protein expression by flow cytometry and western blotting. Academic Press

Marks, D. I., Clifton-Hadley, L., Copland, M., Hussain, J., Menne, T. F., McMillan, A., Moorman, A. V., Morley, N., Okasha, D., Patel, B., Patrick, P., Potter, M. N., Rowntree, C. J., Kirkwood, A. A., Fielding, A. K. (2022) In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. Lancet Haematology, 9, pp. e276-e288. (doi: 10.1016/S2352-3026(22)00036-9)

Pancheva, A., Wheadon, H., Rogers, S., Otto, T. D. (2022) Using topic modeling to detect cellular crosstalk in scRNA-seq. PLoS Computational Biology, 18, (doi: 10.1371/journal.pcbi.1009975)

Copland, M., Slade, D., McIlroy, G., Horne, G., Byrne, J. L., Rothwell, K., Brock, K., De Lavallade, H., Craddock, C., Clark, R. E., Smith, M. L., Fletcher, R., Bishop, R., Milojkovic, D., Yap, C. (2022) Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematology, 9, pp. e121-e132. (doi: 10.1016/S2352-3026(21)00370-7)

Nakasone, M. A., Majorek, K. A., Gabrielsen, M., Sibbet, G. J., Smith, B. O., Huang, D. T. (2022) Structure of UBE2K-Ub/E3/polyUb reveals mechanisms of K48-linked Ub chain extension. Nature Chemical Biology, 18, pp. 422-431. (doi: 10.1038/s41589-021-00952-x)

de Beauchamp, L., Himonas, E., Helgason, G. V. (2022) Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia, 36, pp. 1-12. (doi: 10.1038/s41375-021-01416-w)

Love, S. B. et al. (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23, (doi: 10.1186/s13063-022-06680-4)

Dennis, M., Thomas, I. F., Ariti, C., Upton, L., Burnett, A. K., Gilkes, A., Radia, R., Hemmaway, C., Mehta, P., Knapper, S., Clark, R. E., Copland, M., Russell, N., Hills, R. K. (2021) Randomised evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances, 5, pp. 5621-5625. (doi: 10.1182/bloodadvances.2021005038)

Darici, S., Zavatti, M., Braglia, L., Accordi, B., Serafin, V., Horne, G. A., Manzoli, L., Palumbo, C., Huang, X., Jørgensen, H. G., Marmiroli, S. (2021) Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. Advances in Biological Regulation, 82, (doi: 10.1016/j.jbior.2021.100830)

Rice, S., Jackson, T., Crump, N. T., Fordham, N., Elliott, N., O'Byrne, S., del Mar Lara Fanego, M., Addy, D., Crabb, T., Dryden, C., Inglott, S., Ladon, D., Wright, G., Bartram, J., Ancliff, P., Mead, A. J., Halsey, C., Roberts, I., Milne, T. A., Roy, A. (2021) A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program. Nature Communications, 12, (doi: 10.1038/s41467-021-27270-z)

Malouf, C., Antunes, E. T.B., O'Dwyer, M., Jakobczyk, H., Sahm, F., Landua, S.-L., Anderson, R. A., Soufi, A., Halsey, C., Ottersbach, K. (2021) MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia. Blood, 138, pp. 2066-2092. (doi: 10.1182/blood.2020006610)

Zanetti, C. et al. (2021) The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood, 138, pp. 1870-1884. (doi: 10.1182/blood.2021011557)

Pujol-Navarro, N., Al Qaraghuli, M. M., Kubiak-Ossowska, K., Alsaadi, M. M., Horne, G. A., Soutar, R. L., Paspali, E., Ferro, V. A., Williams, M. T.S., Mulheran, P. A. (2021) Multiple myeloma: therapeutic delivery of antibodies and aptamers. Therapeutic Delivery, 12, pp. 705-722. (doi: 10.4155/tde-2021-0041)

Ianniciello, A., Zarou, M. M., Rattigan, K. M., Scott, M., Dawson, A., Dunn, K., Brabcova, Z., Kalkman, E. R., Nixon, C., Michie, A. M., Copland, M., Vetrie, D., Ambler, M., Saxty, B., Helgason, G. V. (2021) ULK1 inhibition promotes oxidative stress–induced differentiation and sensitizes leukemic stem cells to targeted therapy. Science Translational Medicine, 13, (doi: 10.1126/scitranslmed.abd5016)

Ianniciello, A., Helgason, G. V. (2021) Autophagy in hematopoiesis and leukemogenesis. Academic Press

Aung, M. M. K., Mills, M. L., Bittencourt-Silvestre, J., Keeshan, K. (2021) Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia. Molecular Oncology, 15, pp. 2253-2272. (doi: 10.1002/1878-0261.12899)

Patterson, S. D., Huang, X., Jørgensen, H. G., Michie, A. M. (2021) Transcriptional regulation by the NFAT family in acute myeloid leukaemia. Hemato, 2, pp. 556-571. (doi: 10.3390/hemato2030035)

Marmiroli, S., Huang, X., Serafin, V., Michie, A. M. (2021) Editorial: Special issue on innovative multi-disciplinary approaches for precision studies in leukemia. Frontiers in Oncology, 11, (doi: 10.3389/fonc.2021.744009)

Halsey, C., Escherich, G. (2021) A “Goldilocks” approach to CNS leukaemia is needed. Blood, 138, pp. 288-289. (doi: 10.1182/blood.2021011461)

Welisch, G., Twelves, C., Plummer, R., Evans, J., Danson, S., Symeonides, S., Halsey, C., Jones, R., Hanna, C., Gallagher, P., Walls, G., Taylor, K., Barnett, S., Forde, C., White, M., Williams, C., El Badri, S., Chipole, B.'e. D., Keith, N. (2021) First in Human: who and what makes a cancer phase 1 trial and why are they so important? (doi: 10.17605/OSF.IO/KWHQF)

Andrés-Jensen, L. et al. (2021) Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. Lancet Haematology, 8, pp. e513-e523. (doi: 10.1016/S2352-3026(21)00136-8)

Chantkran, W., Hsieh, Y.-C., Zheleva, D., Frame, S., Wheadon, H., Copland, M. (2021) Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. Cell Death Discovery, 7, (doi: 10.1038/s41420-021-00496-y)

Massett, M. E., Monaghan, L., Patterson, S., Mannion, N., Bunschoten, R. P., Hoose, A., Marmiroli, S., Liskamp, R. M.J., Jørgensen, H. G., Vetrie, D., Michie, A. M., Huang, X. (2021) A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival. Cell Death and Disease, 12, (doi: 10.1038/s41419-021-03738-0)

Zarou, M.-M., Vazquez, A., Helgason, G. V. (2021) Folate metabolism: a re-emerging therapeutic target in haematological cancers. Leukemia, 35, pp. 1539-1551. (doi: 10.1038/s41375-021-01189-2)

Horne, G. A., Laird, J., Latif, A.-L., Irvine, D., Wilson, M., Douglas, K. (2021) The implications of CAR-T cell therapy on apheresis services: a Scottish perspective. Journal of Clinical Apheresis, 36, pp. 513-515. (doi: 10.1002/jca.21871)

Hsieh, Y.-C., Kirschner, K., Copland, M. (2021) Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia, 35, pp. 1229-1242. (doi: 10.1038/s41375-021-01238-w)

Mooney, L., Goodyear, C. S., Chandra, T., Kirschner, K., Copland, M., Petrie, M. C., Lang, N. N. (2021) Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 135, pp. 991-1007. (doi: 10.1042/CS20200306)

Shi, Y., Beckett, M. C., Blair, H. J., Tirtakusuma, R., Nakjang, S., Enshaei, A., Halsey, C., Vormoor, J., Heidenreich, O., Krippner-Heidenreich, A., van Delft, F. W. (2021) Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. Haematologica, 106, pp. 1056-1066. (doi: 10.3324/haematol.2019.241026)

Ahmed, S. F., Buetow, L., Gabrielsen, M., Lilla, S., Sibbet, G. J., Sumpton, D., Zanivan, S., Hedley, A., Clark, W., Huang, D. T. (2021) E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK–CBL–CIN85 axis. Oncogene, 40, pp. 2149-2164. (doi: 10.1038/s41388-021-01684-x)

Magnussen, H. M., Huang, D. T. (2021) Identification of a catalytic active but non-aggregating MDM2 RING domain variant. Journal of Molecular Biology, 433, (doi: 10.1016/j.jmb.2021.166807)

Lenk, L., Carlet, M., Vogiatzi, F., Spory, L., Winterberg, D., Cousins, A., Vossen-Gajcy, M., Ibruli, O., Vokuhl, C., Cario, G., El Ayoubi, O., Kramer, L., Ritgen, M., Brüggemann, M., Häsler, R., Schrappe, M., Fuhrmann, S., Halsey, C., Jeremias, I., Hobeika, E., Jumaa, H., Alsadeq, A., Schewe, D. M. (2021) CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia. Communications Biology, 4, (doi: 10.1038/s42003-020-01591-z)

Latif, A.-L. et al. (2021) BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 12, (doi: 10.1038/s41467-020-20378-8)

Keeshan, K. (2021) Superenhancing AML with Trib1. Blood, 137, pp. 8-9. (doi: 10.1182/blood.2020008315)

Humpton, T. J., Nomura, K., Weber, J., Magnussen, H. M., Hock, A. K., Nixon, C., Dhayade, S., Stevenson, D., Huang, D. T., Strathdee, D., Blyth, K., Vousden, K. H. (2021) Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice. Genes and Development, 35, pp. 117-132. (doi: 10.1101/gad.341875.120)

Marensi, V., Keeshan, K. R., MacEwan, D. J. (2021) Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors. Biochemical Pharmacology, 183, (doi: 10.1016/j.bcp.2020.114348)

Klionsky, D. J. et al. (2021) Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) Autophagy, 17, pp. 1-382. (doi: 10.1080/15548627.2020.1797280)

McMillan, H. D., Keeshan, K., Dunbier, A. K., Mace, P. D. (2021) Structure vs. Function of TRIB1—Myeloid Neoplasms and Beyond. Cancers, 13, (doi: 10.3390/cancers13123060)

Parry, N., Wheadon, H., Copland, M. (2021) The application of BH3 mimetics in myeloid leukemias. Cell Death and Disease, 12, (doi: 10.1038/s41419-021-03500-6)

McAllister, M., Constancio, V., Patek, S., Gan, H., Bailey, P., Wheadon, H., Underwood, M., Leung, H., Edwards, J. (2020) Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naïve prostate cancer. Prostate, 80, pp. 1353-1364. (doi: 10.1002/pros.24064)

Kemp, O., Horne, G. A., Soutar, R. (2020) The psychological impact of COVID19 on a shielding high-risk cohort. Scottish Medical Journal, 65, pp. 120-122. (doi: 10.1177/0036933020951900)

Savino, A. M. et al. (2020) Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on Stearoyl CoA desaturase. Nature Cancer, 1, pp. 998-1009. (doi: 10.1038/s43018-020-00115-2)

Richmond, L., Keeshan, K. (2020) Pseudokinases: a tribble‐edged sword. FEBS Journal, 287, pp. 4170-4182. (doi: 10.1111/febs.15096)

Chatrin, C., Gabrielsen, M., Buetow, L., Nakasone, M. A., Ahmed, S. F., Sumpton, D., Sibbet, G. J., Smith, B. O., Huang, D. T. (2020) Structural insights into ADP-ribosylation of ubiquitin by Deltex family E3 ubiquitin ligases. Science Advances, 6, (doi: 10.1126/sciadv.abc0418)

Darici, S., Alkhaldi, H., Horne, G., Jørgensen, H. G., Marmiroli, S., Huang, X. (2020) Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence. Journal of Clinical Medicine, 9, (doi: 10.3390/jcm9092934)

Ahmed, S. F., Buetow, L., Gabrielsen, M., Lilla, S., Chatrin, C., Sibbet, G. J., Zanivan, S., Huang, D. T. (2020) DELTEX2 C-terminal domain recognizes and recruits ADP-ribosylated proteins for ubiquitination. Science Advances, 6, (doi: 10.1126/sciadv.abc0629)

Mitxitorena, I., Somma, D., Mitchell, J. P., Lepistö, M., Tyrchan, C., Smith, E. L., Kiely, P. A., Walden, H., Keeshan, K., Carmody, R. J. (2020) The deubiquitinase USP7 uses a distinct ubiquitin-like domain to deubiquitinate NF-ĸB subunits. Journal of Biological Chemistry, 295, pp. 11754-11763. (doi: 10.1074/jbc.RA120.014113)

Azar, A. A., Michie, A. M., Tarafdar, A., Malik, N., Menon, G. K., Till, K. J., Vlatković, N., Slipsky, J. R. (2020) A novel transgenic mouse strain expressing PKCβII demonstrates expansion of B1 and marginal zone B cell populations. Scientific Reports, 10, (doi: 10.1038/s41598-020-70191-y)

Horne, G., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A.-L., Dixon-Hughes, J., McMahon, L., Cony-Makhoul, P., Byrne, J., Smith, G., Koschmeider, S., Brümmendorf, T.H., Schafhausen, P., Gallipoli, P., Thomson, F., Cong, W., Clark, R. E., Milojkovic, D., Helgason, G. V., Foroni, L., Nicoloni, F. E., Holyoake, T. L., Copland, M. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34, pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9)

Abdelrasoul, H., Vadakumchery, A., Werner, M., Lenk, L., Khadour, A., Young, M., El Ayoubi, O., Vogiatzi, F., Krämer, M., Schmid, V., Chen, Z., Yousafzai, Y., Cario, G., Schrappe, M., Müschen, M., Halsey, C., Mulaw, M. A., Schewe, D. M., Hobeika, E., Alsadeq, A., Jumaa, H. (2020) Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Nature Communications, 11, (doi: 10.1038/s41467-020-16927-w)

Kinstrie, R., Horne, G., Morrison, H., Irvine, D., Munje, C., Gómez Castañeda, E., Moka, H. A., Dunn, K., Cassels, J., Parry, N., Clarke, C., Scott, M., Clark, R. E., Holyoake, T. L., Wheadon, H., Copland, M. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34, pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5)

Sarrou, E., Richmond, L., Carmody, R. J., Gibson, B., Keeshan, K. (2020) CRISPR gene editing of murine blood stem and progenitor cells induces MLL-AF9 chromosomal translocation and MLL-AF9 leukaemogenesis. International Journal of Molecular Sciences, 21, (doi: 10.3390/ijms21124266)

Magnussen, H. M., Ahmed, S. F., Sibbet, G. J., Hristova, V. A., Nomura, K., Hock, A. K., Archibald, L. J., Jamieson, A. G., Fushman, D., Vousden, K. H., Weissman, A. M., Huang, D. T. (2020) Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain. Nature Communications, 11, (doi: 10.1038/s41467-020-15783-y)

Sepp, K., Lee, M., Bluntzer, M., Helgason, G. V., Hulme, A. N., Brunton, V. G. (2020) Utilizing stimulated Raman scattering microscopy to study intracellular distribution of label-free ponatinib in live cells. Journal of Medicinal Chemistry, 63, pp. 2028-2034. (doi: 10.1021/acs.jmedchem.9b01546)

Walker, D. A., Meijer, L., Coyle, B., Halsey, C. (2020) Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials. Lancet Child and Adolescent Health, 4, pp. 242-250. (doi: 10.1016/S2352-4642(19)30333-5)

Forster, V. J., Bell, G., Halsey, C. (2020) Should nitrous oxide ever be used in oncology patients receiving methotrexate therapy? Pediatric Anesthesia, 30, pp. 9-16. (doi: 10.1111/pan.13760)

Vetrie, D., Helgason, V., Copland, M. (2020) The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nature Reviews Cancer, 20, pp. 158-173. (doi: 10.1038/s41568-019-0230-9)

Collins, P. E., Somma, D., Kerrigan, D., Herrington, F., Keeshan, K. R., Nibbs, R. J.B., Carmody, R. J. (2019) The IκB-protein BCL-3 controls toll-like receptor-induced MAPK activity by promoting TPL-2 degradation in the nucleus. Proceedings of the National Academy of Sciences of the United States of America, 116, pp. 25828-25838. (doi: 10.1073/pnas.1900408116)

Smith, E. L., Somma, D., Kerrigan, D., McIntyre, Z., Cole, J. J., Liang, K. L., Kiely, P. A., Keeshan, K., Carmody, R. J. (2019) The regulation of sequence specific NF-ĸB DNA binding and transcription by IKKβ Phosphorylation of NF-ĸB p50 at Serine 80. Nucleic Acids Research, 47, pp. 11151-11161. (doi: 10.1093/nar/gkz873)

Yousafzai, Y. M., Smith, L., Smith, A., Bhatti, S., Gardiner, M., Cousins, A., Fee, F., Chudleigh, S., Spence, A., Taylor, W., Heaney, N., Gibson, B., Graham, G., Halsey, C. (2019) Use of quantitative polymerase chain reaction (qPCR) for the diagnosis and monitoring of CNS leukaemia. Leukemia Research, 87, (doi: 10.1016/j.leukres.2019.106232)

Malik, N., Dunn, K. M., Cassels, J., Hay, J., Estell, C., Sansom, O. J., Michie, A. M. (2019) mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific Reports, 9, (doi: 10.1038/s41598-019-53141-1)

Claudiani, S., Metelli, S., Kamvar, R., Szydlo, R., Khan, A., Byrne, J., Gallipoli, P., Bulley, S. J., Horne, G. A., Rothwell, K., Copland, M., Clark, R. E., Khorashad, J. S., Foroni, L., Milojkovic, D., Apperley, J. F. (2019) Introducing a predictive score for successful treatment free remission in chronic myeloid leukemia (CML) Blood, 134, pp. 26. (doi: 10.1182/blood-2019-131500)

Hay, J., Moles, M. W., Cassels, J., Michie, A. M. (2019) Subcellular fractionation of primary chronic lymphocytic leukemia cells to monitor nuclear/ cytoplasmic protein trafficking. Journal of Visualized Experiments, (doi: 10.3791/60426)

Mussai, F., Wheat, R., Sarrou, E., Booth, S., Stavrou, V., Fultang, L., Perry, T., Kearns, P., Cheng, P., Keeshan, K., Craddock, C., De Santo, C. (2019) Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. International Journal of Cancer, 145, pp. 2201-2208. (doi: 10.1002/ijc.32028)

Wheadon, H., Busch, C. (2019) Bone marrow niche crosses paths with BMPs: a road to protection and persistence in CML. Biochemical Society Transactions, 47, pp. 1307-1325. (doi: 10.1042/BST20190221)

Hayatigolkhatmi, K., Padroni, G., Su, W., Fang, L., Gómez-Castañeda, E., Hsieh, Y.C., Jackson, L., Pellicano, F., Burley, G.A., Jørgensen, H.G. (2019) An investigation of targeted inhibition of transcription factor activity with pyrrole imidazole polyamide (PA) in chronic myeloid leukemia (CML) blast crisis cells. Bioorganic and Medicinal Chemistry Letters, 29, pp. 2622-2625. (doi: 10.1016/j.bmcl.2019.07.049)

Gabrielsen, M., Buetow, L., Kowalczyk, D., Zhang, W., Sidhu, S. S., Huang, D. T. (2019) Identification and characterization of mutations in ubiquitin required for non-covalent dimer formation. Structure, 27, pp. 1452-1459.e4. (doi: 10.1016/j.str.2019.06.008)

Matheson, E. C., Thomas, H., Case, M., Blair, H., Jackson, R. K., Masic, D., Veal, G., Halsey, C., Newell, D. R., Vormoor, J., Irving, J. A.E. (2019) Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM. Haematologica, 104, pp. 1804-1811. (doi: 10.3324/haematol.2017.185975)

Fox, T. A., Horne, G. A., Craddock, C., Cook, G., O'Brien, S., Fox, S., Hockaday, A., Silk, G., Hillmen, P. (2019) Trial re-investment to build better research for better impact. Lancet, 394, pp. 635-636. (doi: 10.1016/S0140-6736(19)31363-7)

Monaghan, L., Massett, M. E., Bunschoten, R. P., Hoose, A., Pirvan, P.-A., Liskamp, R. M.J., Jørgensen, H. G., Huang, X. (2019) The emerging role of H3K9me3 as a potential therapeutic target in acute myeloid leukaemia. Frontiers in Oncology, 9, (doi: 10.3389/fonc.2019.00705)

Copland, M. (2019) Is there a role for dose modification of TKI therapy in CML. Current Hematologic Malignancy Reports, 14, pp. 337-345. (doi: 10.1007/s11899-019-00524-w)

Bugler, J., Kinstrie, R., Scott, M. T., Vetrie, D. (2019) Epigenetic reprogramming and emerging epigenetic therapies in CML. Frontiers in Cell and Developmental Biology, 7, (doi: 10.3389/fcell.2019.00136)

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., Byrne, J., de Lavallade, H., Osborne, W., Robinson, L., O’Brien, S. G., Read, L., Foroni, L., Copland, M. (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematology, 6, pp. e375-e383. (doi: 10.1016/S2352-3026(19)30094-8)

Baquero, P., Dawson, A., Helgason, G. V. (2019) Autophagy and mitochondrial metabolism: insights into the role and therapeutic potential in chronic myeloid leukaemia. FEBS Journal, 286, pp. 1271-1283. (doi: 10.1111/febs.14659)

Baquero, P., Dawson, A., Mukhopadhyay, A., Kuntz, E. M., Mitchell, R., Olivares, O., Ianniciello, A., Scott, M. T., Dunn, K., Nicastri, M. C., Winkler, J. D., Michie, A. M., Ryan, K. M., Halsey, C., Gottlieb, E., Keaney, E. P., Murphy, L. O., Amaravadi, R. K., Holyoake, T. L., Helgason, G. V. (2019) Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia, 33, pp. 981-994. (doi: 10.1038/s41375-018-0252-4)

Cosimo, E., Tarafdar, A., Moles, M. W., Holroyd, A. K., Malik, N., Catherwood, M. A., Hay, J., Dunn, K. M., Macdonald, A. M., Guichard, S. M., O'Rourke, D. M., Leach, M. T., Sansom, O. J., Cosulich, S. C., McCaig, A. M., Michie, A. M. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25, pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036)

Patel, A., Sibbet, G. J., Huang, D. T. (2019) Structural insights into non-covalent ubiquitin activation of the cIAP1-UbcH5B~ubiquitin complex. Journal of Biological Chemistry, 294, pp. 1240-1249. (doi: 10.1074/jbc.RA118.006045)

Mitchell, R., Copland, M. (2019) Defining niche interactions to target chronic myeloid leukemia stem cells. Haematologica, 105, pp. 2-4. (doi: 10.3324/haematol.2019.234898)

Smith, L. D., Minton, A. R., Blunt, M. D., Karydis, L. I., Dutton, D. A., Rogers-Broadway, K.-R., Dobson, R., Liu, R., Norster, F., Hogg, E., Ashton-Key, M., Strefford, J. C., Jia, L., Efremov, D. G., Helgason, G. V., Johnson, P. W.M., Stevenson, F. K., Forconi, F., Cragg, M. S., Tumbarello, D. A., Packham, G., Steele, A. J. (2019) BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. Leukemia, 34, pp. 640-644. (doi: 10.1038/s41375-019-0557-y)

Chaudhury, S., O'Connor, C., Cañete, A., Bittencourt-Silvestre, J., Sarrou, E., Prendergast, Á., Choi, J., Johnston, P., Wells, C. A., Gibson, B., Keeshan, K. (2018) Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias. Nature Communications, 9, (doi: 10.1038/s41467-018-07584-1)

Malik, N., Sansom, O. J., Michie, A. M. (2018) The role of mTOR-mediated signals during haemopoiesis and lineage commitment. Biochemical Society Transactions, 46, pp. 1313-1324. (doi: 10.1042/BST20180141)

Alsadeq, A., Lenk, L., Vadakumchery, A., Cousins, A., Vokuhl, C., Khadour, A., Vogiatzi, F., Seyfried, F., Meyer, L.-H., Cario, G., Hobeika, E., Debatin, K.-M., Halsey, C., Schrappe, M., Schewe, D. M., Jumaa, H. (2018) IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia. Blood, 132, pp. 1614-1617. (doi: 10.1182/blood-2018-04-844209)

Halsey, C. (2018) Challenging "privileged" stereotypes - leukemic blasts and the central nervous system. Leukemia Research, 73, pp. 76-77. (doi: 10.1016/j.leukres.2018.08.013)

Salomé, M., Hopcroft, L., Keeshan, K. (2018) Inverse and correlative relationships between TRIBBLES genes indicate non-redundant functions during normal and malignant hemopoiesis. Experimental Hematology, 66, pp. 63-78.e13. (doi: 10.1016/j.exphem.2018.07.005)

Foulkes, D. M., Byrne, D. P., Yeung, W., Shrestha, S., Bailey, F. P., Ferries, S., Eyers, C. E., Keeshan, K., Wells, C., Drewry, D. H., Zuercher, W. J., Kannan, N., Eyers, P. A. (2018) Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. Science Signaling, 11, (doi: 10.1126/scisignal.aat7951)

Buetow, L., Gabrielsen, M., Huang, D. (2018) Single-Turnover RING/U-Box E3-Mediated Lysine Discharge Assays. Humana Press

Toofan, P., Busch, C., Morrison, H., O'Brien, S., Jørgensen, H., Copland, M., Wheadon, H. (2018) Chronic myeloid leukemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. Cell Death and Disease, 9, (doi: 10.1038/s41419-018-0905-2)

Cross, N. C.P., White, H. W., Evans, P. A.S., Hancock, J., Copland, M., Milojkovic, D., Mason, J., Craine, S., Mead, A. J. (2018) Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. British Journal of Haematology, 182, pp. 777-788. (doi: 10.1111/bjh.15542)

Ianniciello, A., Rattigan, K. M., Helgason, G. V. (2018) The ins and outs of autophagy and metabolism in hematopoietic and leukemic stem cells: food for thought. Frontiers in Cell and Developmental Biology, 6, (doi: 10.3389/fcell.2018.00120)

Koschmieder, S., Vetrie, D. (2018) Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options. Seminars in Cancer Biology, 51, pp. 180-197. (doi: 10.1016/j.semcancer.2017.07.006)

Wilson, R., Osborne, C., Halsey, C. (2018) The use of Ommaya reservoirs to deliver central nervous system directed chemotherapy in childhood acute lymphoblastic leukaemia. Pediatric Drugs, 20, pp. 293-301. (doi: 10.1007/s40272-018-0298-9)

Newcombe, A. A., Gibson, B. E.S., Keeshan, K. (2018) Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. Experimental Hematology, 63, pp. 1-11. (doi: 10.1016/j.exphem.2018.03.008)

Marciano, G., Da Vela, S., Tria, G., Svergun, D. I., Byron, O., Huang, D. T. (2018) Structure specific recognition protein-1 (SSRP1) is an elongated homodimer that binds histones. Journal of Biological Chemistry, 293, pp. 10071-10083. (doi: 10.1074/jbc.RA117.000994)

Salomé, M., Magee, A., Yalla, K., Chaudhury, S., Sarrou, E., Carmody, R. J., Keeshan, K. (2018) A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling. Cell Death and Disease, 9, (doi: 10.1038/s41419-018-0467-3)

Forster, V., Escherich, G., Halsey, C. (2018) Comment on: Successful use of nitrous oxide during lumbar punctures: a call for nitrous oxide in pediatric oncology clinics. Pediatric Blood and Cancer, 65, (doi: 10.1002/pbc.26930)

Mitchell, R., Hopcroft, L. E.M., Baquero, P., Allan, E. K., Hewit, K., James, D., Hamilton, G., Mukhopadhyay, A., O'Prey, J., Hair, A., Melo, J. V., Chan, E., Ryan, K. M., Maguer-Satta, V., Druker, B. J., Clark, R. E., Mitra, S., Herzyk, P., Nicolini, F. E., Salomoni, P., Helgason, G. V. (2018) Targeting BCR-ABL independent TKI resistance in chronic myeloid leukaemia by mTOR and autophagy inhibition. Journal of the National Cancer Institute, 110, pp. 467-478. (doi: 10.1093/jnci/djx236)

Pellicano, F., Park, L., Hopcroft, L. E.M., Shah, M. M., Jackson, L., Scott, M. T., Clarke, C. J., Sinclair, A., Abraham, S. A., Hair, A., Helgason, G. V., Aspinall-O'Dea, M., Bhatia, R., Leone, G., Kranc, K. R., Whetton, A. D., Holyoake, T. L. (2018) Hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival. Blood, 131, pp. 1532-1544. (doi: 10.1182/blood-2017-05-783845)

Zhang, B. et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nature Medicine, 24, pp. 450-462. (doi: 10.1038/nm.4499)

De Santo, C., Booth, S., Vardon, A., Cousins, A., Tubb, V., Perry, T., Noyvert, B., Beggs, A., Ng, M., Halsey, C., Kearns, P., Cheng, P., Mussai, F. (2018) The arginine metabolome in Acute Lymphoblastic Leukemia can be targeted by the PEG-recombinant Arginase I BCT-100. International Journal of Cancer, 142, pp. 1490-1502. (doi: 10.1002/ijc.31170)

Holroyd, A. K., Michie, A. M. (2018) The role of mTOR-mediated signaling in the regulation of cellular migration. Immunology Letters, 196, pp. 74-79. (doi: 10.1016/j.imlet.2018.01.015)

Sinclair, P. B., Blair, H. H., Ryan, S. L., Buechler, L., Cheng, J., Clayton, J., Hanna, R., Hollern, S., Hawking, Z., Bashton, M., Schwab, C. J., Jones, L., Russell, L. J., Marr, H., Carey, P., Halsey, C., Heidenreich, O., Moorman, A. V., Harrison, C. J. (2018) Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica, 103, pp. 634-644. (doi: 10.3324/haematol.2017.172304)

O'Connor, C., Yalla, K., Salome, M., Moka, H. A., Gómez Castañeda, E., Eyers, P. A., Keeshan, K. (2018) Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2. Oncotarget, 9, pp. 14977-14992. (doi: 10.18632/oncotarget.24525)

Munje, C., Copland, M. (2018) Exploring stem cell heterogeneity in chronic myeloid leukemia. Trends in Cancer, 4, pp. 167-169. (doi: 10.1016/j.trecan.2017.12.001)

Bartram, J., Goulden, N., Wright, G., Adams, S., Brooks, T., Edwards, D., Inglott, S., Yousafzai, Y., Hubank, M., Halsey, C. (2018) High throughput sequencing in acute lymphoblastic leukemia reveals clonal architecture of central nervous system and bone marrow compartments. Haematologica, 103, (doi: 10.3324/haematol.2017.174987)

Hayatigolkhatmi, K., Padroni, G., Su, W., Fang, L., Gómez-Castañeda, E., Hsieh, Y.-C., Jackson, L., Holyoake, T. L., Pellicano, F., Burley, G. A., Jørgensen, H. (2018) Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells. Blood Cells, Molecules, and Diseases, 69, pp. 119-122. (doi: 10.1016/j.bcmd.2017.11.002)

Michie, A.M., Paunovic, V., Harnett, M.M. (2018) Cellular homeostasis: Cell growth and cancer. Elsevier

de Beauchamp, L., Baquero, P., Kuntz, E. M., Gottlieb, E., Helgason, G. V. (2018) Auto-commentary on: “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells” Molecular and Cellular Oncology, 5, (doi: 10.1080/23723556.2017.1403532)

Cousins, A., Markert, E., Degn, M., Olivares, O., Yousafzai, Y. M., Bhatti, S., Herzyk, P., Michie, A., Schmiegelow, K., Gottlieb, E., Halsey, C. (2017) Upregulated cholesterol biosynthesis is a biomarker for isolated central nervous system relapse in acute lymphoblastic leukaemia. Blood, 130,

Lewis, M., Copland, M., Soverini, S., Sadovnik, I., Bedel, A., Prost, S., Italiano, A., Mahon, F.-X. (2017) What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer? Hematological Oncology, 35, pp. 420-423. (doi: 10.1002/hon.2329)

Gabrielsen, M., Buetow, L., Nakasone, M. A., Ahmed, S. F., Sibbet, G. J., Smith, B. O., Zhang, W., Sidhu, S. S., Huang, D. T. (2017) A general strategy for discovery of inhibitors and activators of RING and U-box E3 ligases with ubiquitin variants. Molecular Cell, 68, pp. 456-470.e10. (doi: 10.1016/j.molcel.2017.09.027)

Biggs, M. J.P., Fernandez, M., Thomas, D., Cooper, R., Palma, M., Liao, J., Fazio, T., Dahlberg, C., Wheadon, H., Pallipurath, A., Pandit, A., Kysar, J., Wind, S. J. (2017) The functional response of mesenchymal stem cells to electron-beam patterned elastomeric surfaces presenting micrometer to nanoscale heterogeneous rigidity. Advanced Materials, 29, (doi: 10.1002/adma.201702119)

Kuntz, E. M., Baquero, P., Michie, A. M., Dunn, K., Tardito, S., Holyoake, T. L., Helgason, G. V., Gottlieb, E. (2017) Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nature Medicine, 23, pp. 1234-1240. (doi: 10.1038/nm.4399)

Laing, A. A., Harrison, C. J., Gibson, B. E.S., Keeshan, K. (2017) Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia. Experimental Hematology, 54, pp. 40-50. (doi: 10.1016/j.exphem.2017.06.007)

Sarrou, E., Gibson, B., Keeshan, K. (2017) Absence of Mcm6 mimics haemopoietic ageing and has implications for leukaemic transformation. (doi: 10.1016/j.exphem.2017.06.134)

Brock, K., Billingham, L., Copland, M., Siddique, S., Sirovica, M., Yap, C. (2017) Implementing the EffTox dose-finding design in the Matchpoint trial. BMC Medical Research Methodology, 17, (doi: 10.1186/s12874-017-0381-x)

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., Byrne, J. L., de Lavallade, H., O'Brien, S. G., Coffey, T., Foroni, L., Copland, M. (2017) De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematology, 4, pp. e310-e316. (doi: 10.1016/S2352-3026(17)30066-2)

Ganugula, R., Arora, M., Jaisamut, P., Wiwattanapatapee, R., Jørgensen, H. G., Venkatpurwar, V. P., Zhou, B., Rodrigues Hoffmann, A., Basu, R., Guo, S., Ravi Kumar, M. N. V. (2017) Nano-curcumin safely prevents streptozotocin-induced inflammation and apoptosis in pancreatic ß-cells for effective management of type 1 diabetes mellitus. British Journal of Pharmacology, 174, pp. 2074-2084. (doi: 10.1111/bph.13816)

Nomura, K., Klejnot, M., Kowalczyk, D., Hock, A. K., Sibbet, G. J., Vousden, K., Huang, D. T. (2017) Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity. Nature Structural and Molecular Biology, 24, pp. 578-587. (doi: 10.1038/nsmb.3414)

Carmody, R., Keeshan, K. (2017) The Tribble with APL: a new road to therapy. Cancer Cell, 31, pp. 612-613. (doi: 10.1016/j.ccell.2017.04.011)

Ben Batalla, I., Erdmann, R., Jorgensen, H., Mitchell, R., Ernst, T., von Amsberg, G., Schafhausen, P., Velthaus, J. L., Rankin, S., Clark, R. E., Koschmieder, S., Schultze, A., Mitra, S., Vandenberghe, P., Bru mmendorf, T. H., Carmeliet, P., Hochhaus, A., Pantel, K., Bokemeyer, C., Helgason, G. V., Holyoake, T. L., Loges, S. (2017) Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clinical Cancer Research, 23, pp. 2289-2300. (doi: 10.1158/1078-0432.CCR-16-1930)

Forster, V. J., van Delft, F. W., Baird, S. F., Mair, S., Skinner, R., Halsey, C. (2017) Reply: Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect. Cancer Chemotherapy and Pharmacology, 79, pp. 841-842. (doi: 10.1007/s00280-017-3270-4)

Eyers, P. A., Keeshan, K., Kannan, N. (2017) Tribbles in the 21st Century: the evolving roles of Tribbles pseudokinases in biology and disease. Trends in Cell Biology, 27, pp. 284-298. (doi: 10.1016/j.tcb.2016.11.002)

Holyoake, T. L., Vetrie, D. (2017) The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood, 129, pp. 1595-1606. (doi: 10.1182/blood-2016-09-696013)

Ahmed, A., Wan, X., Mitxitorena, I., Lindsay, A. J., Pandolfi, P. P., McCaffrey, M. W., Keeshan, K., Chen, Y. H., Carmody, R. J. (2017) Regulation of NF-κB by PML and PML-RARα. Scientific Reports, 7, (doi: 10.1038/srep44539)

Cousins, A. F., Olivares, O., Michie, A. M., Gottlieb, E., Halsey, C. (2017) Association of CNS Involvement in Childhood Acute Lymphoblastic Leukaemia with Cholesterol Biosynthesis Upregulation. (doi: 10.1016/S0140-6736(17)30431-2)

Tarafdar, A., Hopcroft, L. E.M., Gallipolli, P., Pellicano, F., Cassels, J., Hair, A., Korfi, K., Jørgensen, H. G., Vetrie, D., Holyoake, T. L., Michie, A. M. (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 129, pp. 199-208. (doi: 10.1182/blood-2016-09-742049)

Oruganti, S.R., Torres, D.J., Krebsbach, S., Asperti-Boursin, F., Winters, J., Matlawska-Wasowska, K., Winter, S.S., Halsey, C., Cannon, J.L. (2017) CARMA1 is a novel regulator of T-ALL disease and leukemic cell migration to the CNS. Leukemia, 31, pp. 255-258. (doi: 10.1038/leu.2016.272)

Lewis, N. S., Lewis, E. E.L., Mullin, M., Wheadon, H., Dalby, M. J., Berry, C. C. (2017) Magnetically levitated mesenchymal stem cell spheroids cultured with a collagen gel maintain phenotype and quiescence. Journal of Tissue Engineering, 8, pp. 1-11. (doi: 10.1177/2041731417704428)

Horne, G. A., Copland, M. (2017) Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. Expert Opinion on Drug Discovery, 12, pp. 465-474. (doi: 10.1080/17460441.2017.1303477)

Jackson, L., Gómez-Castañeda, E., Jørgensen, H. G., Hopcroft, L. E.M., Rogers, S., Holyoake, T. L., Huang, X. (2017) Oncogene addiction in chronic myeloid leukaemia. John Wiley & Sons, Ltd

Horne, G., Jackson, L., Helgason, V., Holyoake, T. L. (2017) Stem cell guardians – old and new perspectives in LSC biology. Current Drug Targets, 18, pp. 405-413. (doi: 10.2174/1389450117666160712092944)

Kinstrie, R., Karamitros, D., Goardon, N., Morrison, H., Hamblin, M., Robinson, L., Clark, R. E., Copland, M., Vyas, P. (2016) Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. Blood Advances, 1, pp. 160-169. (doi: 10.1182/bloodadvances.2016000810)

Horne, G. A., Morrison, H., Campbell, V., Kinstrie, R., Cassels, J., Hair, A., Vetrie, D., Wheadon, H., Holyoake, T. L., Copland, M. (2016) Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Chaudhury, S. S., Wheadon, H., Gibson, B., Keeshan, K. (2016) The Bone Marrow Niche Distinguishes Young and Old Leukemia.

Forster, V. J., van Delft, F. W., Baird, S. F., Mair, S., Skinner, R., Halsey, C. (2016) Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemotherapy and Pharmacology, 78, pp. 1093-1096. (doi: 10.1007/s00280-016-3153-0)

Scott, M. T., Korfi, K., Saffrey, P., Hopcroft, L. E.M., Kinstrie, R., Pellicano, F., Guenther, C., Gallipoli, P., Cruz, M., Dunn, K., Jorgensen, H. G., Cassels, J. E., Hamilon, A., Crossan, A., Sinclair, A., Holyoake, T. L., Vetrie, D. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6, pp. 1248-1257. (doi: 10.1158/2159-8290.CD-16-0263)

Toofan, P., Wheadon, H. (2016) Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis. Biochemical Society Transactions, 44, pp. 1455-1463. (doi: 10.1042/BST20160104)

O'Connor, C., Lohan, F., Campos, J., Ohlsson, E., Salome, M., Forde, C., Artschwager, R., Liskamp, R. M., Cahill, M. A., Kiely, P. A., Porse, B., Keeshan, K. (2016) The presence of C/EBPα and its degradation are both required for TRIB2 mediated leukaemia. Oncogene, 35, pp. 5272-5281. (doi: 10.1038/onc.2016.66)

Buetow, L., Huang, D. T. (2016) Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nature Reviews Molecular Cell Biology, 17, pp. 626-642. (doi: 10.1038/nrm.2016.91)

Keeshan, K., Vieugué, P., Chaudhury, S., Rishi, L., Gaillard, C., LIang, L., Garcia, E., Nakumura, T., Omidvar, N., Kogan, S. C. (2016) Co-operative leukaemogenesis in acute myeloid leukaemia and acute promyelocytic leukaemia reveal C/EBPα as a common target of TRIB1 and PML/RARA. Haematologica, 101, pp. 1228-1236. (doi: 10.3324/haematol.2015.138503)

Lewis, E. E. L., Wheadon, H., Lewis, N., Yang, J., Mullin, M., Hursthouse, A., Stirling, D., Dalby, M. J., Berry, C. C. (2016) A quiescent, regeneration-responsive tissue engineered mesenchymal stem cell bone marrow niche model via magnetic levitation. ACS Nano, 10, pp. 8346-8354. (doi: 10.1021/acsnano.6b02841)

Buetow, L., Tria, G., Ahmed, S. F., Hock, A., Dou, H., Sibbet, G. J., Svergun, D. I., Huang, D. T. (2016) Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation. BMC Biology, 14, (doi: 10.1186/s12915-016-0298-6)

Liang, K. L., Paredes, R., Carmody, R., Eyers, P. A., Meyer, S., McCarthy, T. V., Keeshan, K. (2016) Human TRIB2 oscillates during the cell cycle and promotes ubiquitination and degradation of CDC25C. International Journal of Molecular Sciences, 17, (doi: 10.3390/ijms17091378)

Sinclair, A., Park, L., Shah, M., Drotar, M., Calaminus, S., Hopcroft, L. E.M., Kinstrie, R., Guitart, A. V., Dunn, K., Abraham, S. A., Sansom, O., Michie, A. M., Machesky, L., Kranc, K. R., Graham, G. J., Pellicano, F., Holyoake, T. (2016) CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 128, pp. 371-383. (doi: 10.1182/blood-2015-08-661785)

Laidlaw, K. M.E., Berhan, S., Liu, S., Silvestri, G., Holyoake, T. L., Frank, D. A., Aggarwal, B., Bonner, M. Y., Perrotti, D., Jorgensen, H. G., Arbiser, J. L. (2016) Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget, 7, pp. 51651-51664. (doi: 10.18632/oncotarget.10541)

Abraham, S. A., Hopcroft, L. E.M., Carrick, E., Drotar, M. E., Dunn, K., Williamson, A. J.K., Korfi, K., Baquero, P., Park, L. E., Scott, M. T., Pellicano, F., Pierce, A., Copland, M., Nourse, C., Grimmond, S. M., Vetrie, D., Whetton, A. D., Holyoake, T. L. (2016) Dual targeting of P53 and C-MYC induces selective elimination of leukemic stem cells. Nature, 534, pp. 341-346. (doi: 10.1038/nature18288)

Chaudhury, S., Gibson, B., Keeshan, K. (2016) The Impact of Cellular Age on Leukaemic Transformation.

Schmiegelow, K., Attarbaschi, A., Barzilai, S., Escherich, G., Frandsen, T. L., Halsey, C., Hough, R., Jeha, S., Kato, M., Liang, D.-C., Mikkelsen, T. S., Moricke, A., Niinimaki, R., Piette, C., Putti, M. C., Raetz, E., Silverman, L. B., Skinner, R., Tuckuviene, R., van der Sluis, I., Zapotocka, E. (2016) Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncology, 17, pp. e231-e239. (doi: 10.1016/S1470-2045(16)30035-3)

Sarrou, S., Gibson, B., Keeshan, K. (2016) Efficient Genome Editing of Mouse Hematopoietic Cells Using Crispr/Cas9 Technology.

Salomè, M., Keeshan, K. (2016) TRIB2 Regulates the Cell Cycle Under Stress Conditions in a Murine Cell Model of Leukaemia.

Yalla, K., O'Connor, C., Campos, J., Keeshan, K. (2016) TRIB2 Transformed GMP is the Myeloid Leukaemia Initiating Cell.

Middleton, O., Wheadon, H., Michie, A. (2016) Classical complement pathway. Elsevier

Michie, A.M., Tarafdar, A., Gallipoli, P., Pellicano, F., Hopcroft, L., Korfi, K., Cassels, J., Jorgensen, H.J., Vetrie, D., Holyoake, T.L. (2016) CML Cells Actively Evade Host Immune Surveillance Through Cytokine-Mediated Downregulation of MHC-I I Expression. (doi: 10.1111/bjh.14019)

Jackson, L., Hopcroft, L.E.M., Rogers, S., Jorgensen, H., Pellicano, F., Wells, C., Mosbergen, R., Chen, T., Vetrie, D., Holyoake, T.L. (2016) Identifying Genes and Pathways Deregulated in Chronic Myeloid Leukaemia Stem Cells Through Meta-Analysis of Transcriptomic Data. (doi: 10.1111/bjh.14019)

Gómez-Castañeda, E., Hopcroft, L.E.M., Rogers, S., Jorgensen, H.G., Pellicano, F., Vetrie, D., Copland, M., Grimmond, S., Holyoake, T.L. (2016) Uncovering the BCR-ABL1 Tyrosine Kinase Independent Signature in Chronic Myeloid Leukaemia Stem Cells. (doi: 10.1111/bjh.14019)

Irvine, D. A., Zhang, B., Kinstrie, R., Tarafdar, A., Morrison, H., Campbell, V. L., Moka, H. A., Ho, Y., Nixon, C., Manley, P. W., Wheadon, H., Goodlad, J. R., Holyoake, T. L., Bhatia, R., Copland, M. (2016) Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific Reports, 6, (doi: 10.1038/srep25476)

Brehme, M., Koschmieder, S., Montazeri, M., Copland, M., Oehler, V. G., Radich, J. P., Brümmendorf, T. H.,, Schuppert, A. (2016) Combined population dynamics and entropy modelling supports patient stratification in chronic myeloid leukemia. Scientific Reports, 6, (doi: 10.1038/srep24057)

Schemionek, M., Herrmann, O., Merle Reher, M., Chatain, N., Schubert, C., Costa, I. G., Haenzelmann, S., Gusmao, E. G., Kintsler, S., Braunschweig, T., Hamilton, A., Helgason, G.V., Copland, M., Schwab, A., Müller-Tidow, C., Li, S., Holyoake, T. L., Brümmendorf, T. H., Koschmieder, S. (2016) MTSS1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia, 30, pp. 823-830. (doi: 10.1038/leu.2015.329)

Liang, K. L., O'Connor, C., Veiga, J. P., McCarthy, T. V., Keeshan, K. (2016) TRIB2 regulates normal and stress-induced thymocyte proliferation. Cell Discovery, 2, (doi: 10.1038/celldisc.2015.50)

Marciano, G., Huang, D.T. (2016) Structure of the human histone chaperone FACT Spt16 N-terminal domain. Acta Crystallographica. Section F: Structural Biology Communications, 72, pp. 121-128. (doi: 10.1107/s2053230x15024565)

Karvela, M., Baquero, P., Kuntz, E. M., Mukhopadhyay, A., Mitchell, R., Allan, E. K., Chan, E., Kranc, K. R., Calabretta, B., Salomoni, P., Gottlieb, E., Holyoake, T. L., Helgason, G. V. (2016) ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells. Autophagy, 12, pp. 936-948. (doi: 10.1080/15548627.2016.1162359)

Selman, C., Sinclair, A., Pedroni, S. M.A., Irvine, E. E., Michie, A. M., Withers, D. J. (2016) Evidence that hematopoietic stem cell function is preserved during aging in long-lived S6K1 mutant mice. Oncotarget, 7, (doi: 10.18632/oncotarget.8729)

Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L., Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L., Bhatia, R. (2016) Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells. Blood, 128, pp. 2671-2682. (doi: 10.1182/blood-2015-11-679928)

Williams, M. T.S., Yousafzai, Y. M., Elder, A., Rehe, K., Bomken, S., Frishman-Levy, L., Tavor, S., Sinclair, P., Dormon, K., Masic, D., Perry, T., Weston, V. J., Kearns, P., Blair, H., Russell, L. J., Heidenreich, O., Irving, J. A.E., Izraeli, S., Vormoor, J., Graham, G., Halsey, C. (2016) The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukaemia blasts. Blood, 127, (doi: 10.1182/blood-2015-08-665034)

Nakasone, M., Huang, D. T. (2016) Ubiquitination accomplished: E1 and E2 enzymes were not necessary. Molecular Cell, 62, pp. 807-809. (doi: 10.1016/j.molcel.2016.06.001)

Latif, A.-L., Cole, J. J., Monteiro Campos, J., Clark, W., McGarry, L., Brock, C., Newcombe, A., Keeshan, K., Copland, M., Adams, P. D. (2015) Dual inhibition of MDM2 and BET cooperate to eradicate acute myeloid leukemia. Blood, 126, pp. 674. (doi: 10.1182/blood.V126.23.674.674)

Horne, G. A., Chevassut, T. J.T., Fidler, K., Wynne, C. (2015) Haemolytic anaemia: don't leave it out in the cold. Archives of Disease in Childhood: Education and Practice, 100, pp. 323-330. (doi: 10.1136/archdischild-2014-308132)

Salome, M., Campos, J., Keeshan, K. (2015) TRIB2 and the ubiquitin proteasome system in cancer. Biochemical Society Transactions, 43, pp. 1089-1094. (doi: 10.1042/bst20150103)

Holyoake, T., Vetrie, D. (2015) Cancer: repositioned to kill stem cells. Nature, 525, pp. 328-329. (doi: 10.1038/nature15213)

Pellicano, F., O'Connor, C., Keeshan, K. (2015) An investigation of the leukaemia initiating cell in TRIB2 mediated AML. Experimental Hematology, 43, pp. S88. (doi: 10.1016/j.exphem.2015.06.228)

Chaudhury, S. S., Morison, J. K., Gibson, B. E.S., Keeshan, K. (2015) Insights into cell ontogeny, age and acute myeloid leukaemia. Experimental Hematology, 43, pp. 745-755. (doi: 10.1016/j.exphem.2015.05.008)

Liang, K. L., O'Connor, C., McCarthy, T. V., Keeshan, K. (2015) Investigation of the role of TRIB2 in normal murine hematopoiesis. Experimental Hematology, 43, pp. S77. (doi: 10.1016/j.exphem.2015.06.181)

Olivares, O., Däbritz, J. H. M., King, A., Gottlieb, E., Halsey, C. (2015) Research into cancer metabolomics: towards a clinical metamorphosis. Seminars in Cell and Developmental Biology, 43, pp. 52-64. (doi: 10.1016/j.semcdb.2015.09.008)

Buetow, L., Gabrielsen, M., Anthony, N. G., Dou, H., Patel, A., Aitkenhead, H., Sibbet, G. J., Smith, B. O., Huang, D. T. (2015) Activation of a primed RING E3-E2–ubiquitin complex by non-covalent ubiquitin. Molecular Cell, 58, pp. 297-310. (doi: 10.1016/j.molcel.2015.02.017)

Venkatpurwar, V.P., Rhodes, S., Oien, K.A., Elliott, M.A., Tekwe, C.D., Jorgensen, H.G., Ravi Kumar, M.N.V. (2015) Drug- not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano- and micro-particles: size does not matter. Toxicology, 330, pp. 9-18. (doi: 10.1016/j.tox.2015.01.017)

Nakagawa, R., Vukovic, M., Tarafdar, A., Cosimo, E., Dunn, K., Mccaig, A. M., Holroyd, A., McClanahan, F., Ramsay, A. G., Gribben, J. G., Michie, A. (2015) Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC subversion induces up-regulation of PKC II expression in B lymphocytes. Haematologica, 100, pp. 499-510. (doi: 10.3324/haematol.2014.112276)

O'Connor, C., Campos, J., Osinski, J. M., Gronostajski, R. M., Michie, A., Keeshan, K. (2015) Nfix expression critically modulates early B lymphopoiesis and myelopoiesis. PLoS ONE, 10, (doi: 10.1371/journal.pone.0120102)

Ford, C. A., Petrova, S., Pound, J. D., Voss, J. J.L.P., Melville, L., Paterson, M., Farnworth, S. L., Gallimore, A. M., Cuff, S., Wheadon, H., Dobbin, E., Ogden, C. A., Dumitriu, I. E., Dunbar, D. R., Murray, P. G., Ruckerl, D., Allen, J. E., Hume, D. A., van Rooijen, N., Goodlad, J. R., Freeman, T. C., Gregory, C. D. (2015) Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Current Biology, 25, pp. 577-588. (doi: 10.1016/j.cub.2014.12.059)

Kranc, K. R., Oliveira, D. V., Armesilla-Diaz, A., Pacheco-Leyva, I., Catarina Matias, A., Luisa Escapa, A., Subramani, C., Wheadon, H., Trindade, M., Nichols, J., Kaji, K., Enver, T., Bragança, J. (2015) Acute loss of Cited2 impairs Nanog expression and decreases self-renewal of mouse embryonic stem cells. Stem Cells, 33, pp. 699-712. (doi: 10.1002/stem.1889)

Middleton, O., Cosimo, E., Dobbin, E., McCaig, A.M., Clarke, C., Brant, A.M., Leach, M.T., Michie, A.M., Wheadon, H. (2015) Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia, 29, pp. 107-114. (doi: 10.1038/leu.2014.146)

Holyoake, T. L., Helgason, G. V. (2015) Do we need more drugs for chronic myeloid leukemia? Immunological Reviews, 263, pp. 106-123. (doi: 10.1111/imr.12234)

Igbineweka, N. E., Horne, G. A., Jackson, M. B., Chevassut, T. J. (2015) Low oxygen affinity variant haemoglobin in an elderly woman presenting with low oxygen saturation. Acute Medicine, 14, pp. 72-6.

Horne, G. A., Kinstrie, R., Copland, M. (2015) Novel drug therapies in myelois leukemia: a patent review. Pharmaceutical Patent Analyst, 4, pp. 187-205. (doi: 10.4155/ppa.15.3)